TECHWIRE 30
(CIX: WRAL30)  1,099.18  up arrow+0.52  (0.05 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: Apple)  100.58  up arrow+0.01  (0.01 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NY: QUINTILES)  56.34  up arrow+0.29  (0.52 %)  Updated: 06:40 PM EDT, Aug 21 2014
(OP: BASF SE)  102.70  up arrow+1.23  (1.21 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: BioCryst)  12.61  down arrow-0.48  (-3.67 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: BioDelivery)  13.46  down arrow-0.43  (-3.1 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: CEMP)  9.37  down arrow-0.12  (-1.26 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: Cisco Systems)  24.89  up arrow+0.18  (0.73 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: Cree)  45.07  down arrow-0.32  (-0.71 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: DARA)  1.25  down arrow-0.02  (-1.51 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NY: EMC CORPORATION)  29.62  down arrow-0.08  (-0.27 %)  Updated: 06:40 PM EDT, Aug 21 2014
(NQ: Extreme Networks)  5.23  down arrow-0.05  (-0.95 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: FB)  74.57  down arrow-0.24  (-0.32 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NY: GLAXOSMITHKLINE)  47.70  down arrow-0.11  (-0.23 %)  Updated: 06:40 PM EDT, Aug 21 2014
(NQ: GOOG)  583.37  down arrow-1.12  (-0.19 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NY: IBM)  191.23  up arrow+1.13  (0.59 %)  Updated: 06:40 PM EDT, Aug 21 2014
(NY: LH)  106.82  up arrow+0.67  (0.63 %)  Updated: 06:40 PM EDT, Aug 21 2014
(OP: Lenovo Group)  30.65  up arrow+0.31  (1.01 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NY: MRK)  58.85  down arrow-0.63  (-1.06 %)  Updated: 06:40 PM EDT, Aug 21 2014
(NQ: Microsoft Corp)  45.22  up arrow+0.27  (0.6 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: NTAP)  40.92  down arrow-0.05  (-0.11 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NY: NOVARTIS AG)  88.95  up arrow+0.35  (0.4 %)  Updated: 06:40 PM EDT, Aug 21 2014
(OP: Novozymes A/S)  44.87  down arrow-0.25  (-0.55 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NY: PFIZER)  28.82  down arrow-0.07  (-0.24 %)  Updated: 06:40 PM EDT, Aug 21 2014
(NQ: Pozen)  7.72  up arrow+0.07  (0.92 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NY: RED HAT)  61.57  down arrow-0.11  (-0.18 %)  Updated: 06:40 PM EDT, Aug 21 2014
(NQ: BBRY)  9.85  down arrow-0.32  (-3.1 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: Salix)  158.30  up arrow+1.12  (0.71 %)  Updated: 08:10 PM EDT, Aug 21 2014
(NQ: SQI)  15.06  down arrow-0.09  (-0.59 %)  Updated: 08:10 PM EDT, Aug 21 2014

Posts tagged “Quintiles”

Updated July 31

Premium Lock Next wave in clinical trials? Risk-based monitoring, says Quintiles CEO

Tom Pike, CEO of Quintiles, sees a new wave of business coming for life science services companies. And the world's largest contract research organization is ready to capitalize on "risk-based monitoring," he says in a conference call.

Tom Pike Tom Pike

Updated July 31

As earnings soar, Quintiles ups expectations for 2014

Quintiles       Quintiles, the world's largest life science company, says new business surged 21 percent in its most recent quarter, driving revenues to $1.035 billion compared to $944 million a year ago. Earnings jumped 30 percent to 65 cents per share. Quintiles also adjusted upward its financial expectations for the year.

Updated July 3

Premium Lock Pozen resubmits drug; Amazon to fight FTC; Furiex, Quintiles deals close; Twitter's new CFO

Bulldog In today's Bulldog wrapup of technology and life science news: Pozen resubmits a drug application; Amazon to fight FTC over kid apps purchases; Furiex and Quintiles deals close; Twitter names a new CFO

June 23

Premium Lock Carolinas HealthCare, SAS and Quintiles named Best Places to Work in IT

2014 Computerworld Best Places to Work in IT Every year since 1994, Computerworld has published a list of the 100 Best Places to Work in IT. On Monday, the publication released this year's list.

June 23

Premium Lock Opinion: Pharma follows as the CROs fly

Contract research organizations aren't what they used to be. But, they are where they used to be: in North Carolina.

NC the CRO Epicenter? NC the CRO Epicenter?

June 13

Premium Lock Pharma outsourcing beyond clinical trials paves way for more Quintiles growth

Quintiles CEO Tom Pike says Quintiles' ability to offer pharmas more than simply outsourced clinical trial services will lead to the company's growth. Read more about his comments to analysts and investors at Goldman Sach's healthcare conference.

Quintiles' Goldman Sachs 2014 presentation Quintiles' Goldman Sachs 2014 presentation

June 9

Premium Lock ISR recognizes Quintiles as leader in clinical research services

Quintiles       The contract research organization continues to rack up accolades this month with a new survey from ISR out on Monday that taps Quintiles as an industry leader in Phase I clinical research services.

June 6

Premium Lock Quintiles cracks Chief Information Officer 100 list

Quintiles       Quintiles, the world's largest life science services company, is adding another honor. After being named to the Fortune 500 earlier this week, Quintiles on Friday was selected for the CIO 100 list for information technology innovation.

Updated June 2

Premium Lock Quintiles named to Fortune 500

Quintiles       Quintiles, the Triangle-based international biopharmaceutical giant, was named Monday to the Fortune 500 list of largest U.S. companies ranked by revenue.

Updated May 13

Premium Lock Inside Quintiles' new acquisition: Why make the deal for Encore? Don't expect jobs to move to RTP

Quintiles       Quintiles CEO Tom Pike has said in the past that the world's largest life science services company would keep making acquisitions after going public a year ago. True to his word, Pike is growing Quintiles again in a deal for Houston-based Encore. How does the deal boost the big "Q"? By the way, don't expect any jobs to move to N.C. WRAL TechWire Insiders find out.

Updated May 13

Premium Lock Quintiles acquires 300-employee health information analytics firm

Electronic health records Quintiles, the world's largest provider of life science industry services, is growing a bit bigger but adding more expertise in healthcare analytics through the acquisition of Encore Health Resources.

April 29

Premium Lock From our archives: The Fred Eshelman saga includes one-person startup at PPD to Wilmington's Walk of Fame and now a $1.1B sale of Furiex

Fred Eshelman Looking back at Fred Eshelman's career: A 2009 blog post recapped a tumultuous year for Eshelman and PPD in which the company's stock was hammered and he stepped down as CEO to become executive chairman. But the year was capped with a salute. From there, Eshelman has continued to make headlines.

Updated April 24

Premium Lock Quintiles, Biogen strike 5-year drug development deal

Quintiles, the world's largest provider of life science services such as clinical trials, and pharmaceutical firm Biogen, which has a huge manufacturing facility in RTP, have formed a "collaboration" through which the two firms will develop drug candidates in Biogen's pipeline. But neither company will discuss financial terms of the deal. There may be some hiring at Quintiles for a Biogen-focused team, but Biogen plans no layoffs.

Quintiles teams with Biogen Quintiles teams with Biogen

April 24

Premium Lock Biogen-Quintiles deal brings two RTP heavyweights closer

Biogen's new RTP facility While neither company is talking about the financials involved in their five-year partnership announced Thursday, the firms do say the agreement means the two companies will become much more than RTP neighbors.

March 27

Premium Lock BioDelivery Sciences picks Quintiles to help launch proposed drug

Raleigh-based BioDelivery Sciences recently raised $60 million to help commercialize its proposed chronic pain reliever drug and hopes to win FDA approval for it in June. On Thursday, BDSI said it had chosen Durham-based Quintiles, the world's largest life science services firm, to help take the drug to market. The deal includes formation of a sales force.

How BDSI technology works How BDSI technology works

Updated March 19

Premium Lock Window of opportunity: More life science IPOs in Triangle is good for all

Life Sciences A spate of Triangle life science IPOs raised more total money than those in Boston and New York in 2013, and more followed early this year. Has this open IPO window affected biotech and life science fundraising in the Triangle? Will the window remain open? One area VC suggests we may look back on 2010-2015 as a watershed time for the regional industry.

March 13

Premium Lock Quintiles lowers big stock offering by some $44M

Dennis Gillings, the co-founder of Quintiles, and other investors in the world's largest life science services company, won't be getting as much as expected from an offering of stock that cashes in on a 2013 IPO.

Dennis Gillings Dennis Gillings

Updated March 10

Premium Lock Gillings, Quintiles investors look to cash out $939M in shares

Dennis Gillings, the co-founder of Quintiles, and other investors in the world's largest life science services company, are looking to cash in on Quntiles' IPO from last year. According to an SEC filing made early Monday, they are offering some 17.5 million shares worth $939.3 million.

Dennis Gillings, center, rings in NYSE action Dennis Gillings, center, rings in NYSE action

February 14

Premium Lock In their own words: Quintiles execs praise Novella deal, look for more

Tom Pike An analyst quizzed Quintiles executives about the company's 2013 purchase of near-by Novella. CFO Kevin Gordon and CEO Tom Pike had plenty of good things to say, especially the financial performance. They also said Quintiles continues to look for more deals.

Updated February 13

Premium Lock Quintiles reports first $1B in quarterly service revenues

Quintiles' headquarters    Investors like the overall earnings report and forecast for the coming year. Shares climb in pre-market trading. Says Quintiles CEO Tom Pike. "We are well positioned entering 2014 with the largest backlog in the industry at $9.9 billion dollars which will fuel 2014 constant currency service revenue and earnings growth.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Scroll